Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype

Next Previous
Trial Profile

Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Talabostat (Primary)
  • Indications Adenocarcinoma; Neuroendocrine carcinoma; Prostate cancer
  • Focus First in man; Proof of concept; Registrational; Therapeutic Use
  • Sponsors BioXcel Therapeutics

Most Recent Events

  • 06 Jun 2023 Phase 2a activity threshold for accrual was met and Phase 2b portion of study was initiated to evaluate SCNC variant in a potential registrational randomized study.
  • 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 22 May 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top